iRhythm Holdings, Inc. research snapshot
IRTC AI stock analysis currently reads iRhythm Holdings, Inc. as a digital healthcare company transforming ambulatory cardiac monitoring with its Zio ECG patch ecosystem and FDA-cleared AI analytics. At the July 12, 2026 data cutoff, IRTC traded near $116.13 with an implied market capitalization of about $3.82 billion. The positive case is built on 2026 revenue guidance of $875M to $885M, expanding gross margins above 70%, a path to GAAP profitability, and strong analyst conviction with 14 of 15 analysts rating it a Buy. The caution case is that IRTC is still GAAP unprofitable TTM, has a high debt-to-equity ratio, recently settled a securities class action, and faces competition from Boston Scientific, Medtronic, and other cardiac monitoring entrants. This page is informational research, not investment advice.
Current price
$116.13 intraday reference
Market cap
$3.82 billion
AI score
58 / 100
Rating
Growing digital cardiac monitoring platform with strong revenue trajectory, improving margins, but not yet GAAP profitable
Trend status
Corrective downtrend from 52-week highs, trading well below both moving averages with RSI near neutral
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | iRhythm sells a differentiated ambulatory cardiac monitoring service with Zio ECG patches, AI-powered analytics, and a growing physician install base. Revenue is growing above 20% with expanding gross margins. | Medium-high |
| Moat | The moat comes from FDA-cleared AI algorithms, a large real-world evidence database, brand recognition among cardiologists, EHR integration, and switching costs from physician workflow adoption. However, deep-pocketed competitors like Boston Scientific and Medtronic are investing in competing patch-based solutions. | Medium |
| Management | Management is navigating the transition from iRhythm Technologies to iRhythm Holdings with a focus on operational efficiency, margin expansion, and the upcoming Zio MCT launch in 2027. The class action settlement and data security incident raise governance questions. | Medium |
| Financial trend | Q1 2026 revenue grew 25.7% YoY to $199.39M. Full-year 2026 guidance of $875M to $885M implies 17-18% growth. Gross margin expanded to 70.9%. GAAP net loss narrowed to -$11.35M in Q1 2026 from -$14.22M in Q2 2025. | High |
| Valuation | At $116.13, IRTC trades at approximately 4.8x forward sales, 24x book value, and negative P/E TTM. Enterprise value of about $4.05B represents roughly 5.1x forward revenue. The market is pricing in future profitability but at a premium to established medtech peers. | High |
| Technical trend | Investing.com shows RSI(14) near 47.67 with a neutral daily signal. The stock is well below both its 50-day and 200-day moving averages after falling from 52-week highs of $212. | Medium |
| Risk level | Main risks are GAAP unprofitability, high debt/equity at 452%, class action lawsuit settlement costs, data security incident, FDA regulatory risk, competitive pressure from Boston Scientific and Medtronic, and reimbursement dependency. | Medium-high |
| AI confidence | Descriptive confidence is high for reported financials and market data. Return confidence is lower because the stock price depends on the timeline to sustained GAAP profitability, which is inherently uncertain for a growth-stage healthcare company. | High data confidence |
| Investment certainty | IRTC may appeal to growth-oriented investors who believe in the digital cardiac monitoring thesis and management execution, but it does not yet have the certainty profile suitable for value-oriented or income-focused investors. | Low to medium |
IRTC AI stock forecast
The IRTC AI stock forecast uses scenarios rather than a single price claim. Because IRTC has negative TTM GAAP EPS, the forecast framework uses revenue multiples and analyst consensus as anchors. At the July 12, 2026 reference price of $116.13, forward EV/Revenue of about 4.6x to 5.1x is priced in. Analyst consensus targets average $178.21, implying about 53% upside. These ranges depend on GAAP profitability timeline, revenue growth trajectory, competitive dynamics, and successful Zio MCT launch.
$175 to $215
More likely if revenue growth accelerates above guidance, GAAP profitability is achieved by late 2026 or early 2027, Zio MCT launch in H1 2027 drives adoption, margins continue expanding, and the market re-rates the stock to a higher forward sales multiple.
$140 to $170
More likely if iRhythm delivers on 2026 revenue guidance of $875M to $885M with consistent margin improvement, GAAP losses continue narrowing, analyst targets near the $178 average prove achievable, and competitive pressures remain manageable.
$80 to $110
More likely if GAAP profitability is delayed beyond 2027, litigation or FDA issues emerge, revenue growth decelerates meaningfully, competitive pressure from Boston Scientific or Medtronic intensifies, or the company needs dilutive financing.
IRTC AI technical analysis
IRTC AI technical analysis is cautious as of the July 12, 2026 data cutoff. Investing.com showed a reference price near $116.13, with RSI(14) near 47.67 and a neutral daily technical summary. The stock is well below its 52-week high of $212, having fallen from those levels on litigation, data security, and growth concerns. Google Finance and Yahoo Finance showed price near $116.13 with a 52-week range of $100.85 to $212.00. The setup is vulnerable, and a break below the $100.85 52-week low would open deeper downside.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $116.13 intraday | Investing.com and Google Finance listed this reference on July 10-12, 2026, with a day range of $114.47 to $118.08. |
| Support near 52-week low | $100.85 to $105.00 | The 52-week low of $100.85 was reached in June 2026. This is the critical support zone. A bounce here would be constructive; a break below would be bearish. |
| Deeper support | $85.00 to $95.00 | If the $100.85 low breaks, the next support zone would be the IPO and early trading ranges from the $85 to $95 area. |
| Near resistance | $135.00 to $147.00 | The Goldman Sachs analyst target of $147 provides a near-term resistance reference. The area between $135 and $147 represents the first major overhead supply zone. |
| Upper resistance | $175 to $212 | The 52-week high of $212 and the average analyst target of $178 define the upper resistance zone. A return to this range would require significant positive catalysts. |
| Moving averages | 50-day and 200-day well above current price | Both moving averages are likely well above the current $116 level given the significant decline from the $212 high. The stock is in a downtrend until it reclaims these levels. |
| Momentum | RSI(14) near 47.67 | RSI is neutral, neither oversold nor overbought. This gives little directional signal. Watch for RSI to reach oversold levels near 30 for possible mean-reversion setups. |
| Volume | Avg volume near 560,000 to 620,000 shares | Liquidity is adequate for a mid-cap healthcare stock. Volume around earnings, FDA news, and litigation updates should be monitored for conviction. |
| Volatility | High, driven by earnings, FDA, and litigation | The next earnings date is estimated around July 30, 2026. The stock has high single-stock volatility given its growth-stage profile and overhang from the class action and data security incidents. |
| Invalidation | Close below $100.85 or above $147 | A close below the 52-week low of $100.85 would invalidate the current support structure. A close above $147 would suggest the downtrend may be reversing. |
IRTC AI trading strategy
The IRTC AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with revenue growth, margin trajectory, GAAP profitability timeline, Zio MCT launch progress, litigation, and competitive dynamics.
Given the current downtrend, a trend-following approach would wait for IRTC to establish a higher low above the $100.85 52-week low, reclaim the 50-day moving average, and show improving RSI momentum before considering a long entry.
A break below $100.85 should be respected as a continuation of the downtrend. Position sizing should reflect the high-risk nature of a growth-stage medtech stock with GAAP losses and litigation overhang.
If IRTC approaches the $100.85 to $105 support zone with improving fundamentals (strong Q2 earnings, margin progress, or positive FDA/Zio MCT news), a mean-reversion trade toward $135 could work. Wait for confirmation signals before entry.
Do not assume the 52-week low will hold just because the stock is down significantly. The stock dropped from $212 to $101 for fundamental reasons, and those reasons (GAAP losses, litigation, competition) have not been fully resolved.
Track Q2 2026 earnings (est. July 30, 2026), GAAP profitability progress, 2026 revenue guidance updates, Zio MCT development milestones, FDA regulatory developments, litigation resolution, and competitive positioning against Boston Scientific, Medtronic, and Bardy.
The stock carries event risk around earnings, FDA communications, and litigation developments. Consider reduced position size ahead of binary events and avoid leveraged exposure.
Investment research summary
iRhythm gets paid because cardiologists and health systems need reliable, continuous, AI-enhanced ambulatory cardiac monitoring to detect arrhythmias. Patients wear the Zio patch for up to 14 days, and iRhythm provides the device, AI analysis, and clinical report as an integrated service.
The moat comes from FDA-cleared AI algorithms trained on millions of heartbeats of real-world data, brand recognition among cardiologists, ZioSuite software integration with EHR systems, and physician workflow stickiness. However, larger competitors with more resources are investing in competing patch-based solutions.
The thesis fails if GAAP profitability remains elusive, revenue growth decelerates as the installed base matures, a major competitor like Boston Scientific or Medtronic takes meaningful market share, FDA issues a warning letter or clinical hold, or the debt load restricts strategic flexibility.
Management is executing on operational efficiency and margin expansion while navigating the Zio MCT development cycle. The class action settlement and data security incident are governance concerns that need continued monitoring. The test is whether iRhythm can reach sustained GAAP profitability while maintaining its competitive position.
The shift from Holter monitors to patch-based continuous cardiac monitoring is a long-term structural trend. An aging population, rising atrial fibrillation prevalence, and telemedicine adoption support the thesis. The offset is that large medtech incumbents are aware of this trend and investing aggressively.
At roughly 4.8x forward sales and negative GAAP earnings, IRTC is priced as a growth stock with a premium valuation. Margin of safety is limited unless the company reaches GAAP profitability faster than expected. The valuation depends entirely on future profitability, which carries execution risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IRTC quote reference | $116.13 close on July 10, 2026 | Investing.com IRTC page | July 12, 2026 |
| Market capitalization verification | $3.82B reported, calculated as $116.13 x 32.86M shares = $3.82B | Pineify verification and Google Finance | July 12, 2026 |
| Shares outstanding | 32.86 million basic shares outstanding | Google Finance IRTC page | July 12, 2026 |
| TTM revenue | $787.85 million | Yahoo Finance IRTC statistics | July 12, 2026 |
| TTM GAAP net income | -$27.78 million | Yahoo Finance IRTC statistics | July 12, 2026 |
| TTM GAAP EPS | -$0.86 | Yahoo Finance IRTC statistics | July 12, 2026 |
| Q1 2026 revenue and net earnings | $199.39 million revenue and -$11.35 million GAAP net loss for Q1 2026 | Yahoo Finance IRTC financials | July 12, 2026 |
| 2026 revenue guidance | $875 million to $885 million (17-18% YoY growth) | iRhythm Q1 2026 earnings release & Google Finance | July 12, 2026 |
| Cash and equivalents | $549.62 million at most recent quarter | Yahoo Finance IRTC statistics | July 12, 2026 |
| Analyst consensus | 14 Buy, 1 Hold, 0 Sell. Average price target $178.21 (53% upside) | Google Finance IRTC analyst ratings | July 12, 2026 |
| 52-week range | $100.85 to $212.00 | Google Finance IRTC page | July 12, 2026 |
| Technical indicators | RSI(14) near 47.67, neutral daily signal, price below moving averages | Investing.com IRTC technical analysis | July 12, 2026 |
This IRTC AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell iRhythm Holdings, Inc., and not a promise of future returns. Forecasts are scenario-based estimates from available public data and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
